Tran Eric, Ahmadzadeh Mojgan, Lu Yong-Chen, Gros Alena, Turcotte Simon, Robbins Paul F, Gartner Jared J, Zheng Zhili, Li Yong F, Ray Satyajit, Wunderlich John R, Somerville Robert P, Rosenberg Steven A
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Science. 2015 Dec 11;350(6266):1387-90. doi: 10.1126/science.aad1253. Epub 2015 Oct 29.
It is unknown whether the human immune system frequently mounts a T cell response against mutations expressed by common epithelial cancers. Using a next-generation sequencing approach combined with high-throughput immunologic screening, we demonstrated that tumor-infiltrating lymphocytes (TILs) from 9 out of 10 patients with metastatic gastrointestinal cancers contained CD4(+) and/or CD8(+) T cells that recognized one to three neo-epitopes derived from somatic mutations expressed by the patient's own tumor. There were no immunogenic epitopes shared between these patients. However, we identified in one patient a human leukocyte antigen-C*08:02-restricted T cell receptor from CD8(+) TILs that targeted the KRAS(G12D) hotspot driver mutation found in many human cancers. Thus, a high frequency of patients with common gastrointestinal cancers harbor immunogenic mutations that can potentially be exploited for the development of highly personalized immunotherapies.
目前尚不清楚人类免疫系统是否经常对常见上皮癌所表达的突变产生T细胞反应。通过将新一代测序方法与高通量免疫筛选相结合,我们证明,10例转移性胃肠道癌患者中有9例的肿瘤浸润淋巴细胞(TIL)含有CD4(+)和/或CD8(+) T细胞,这些T细胞识别出一至三个源自患者自身肿瘤所表达的体细胞突变的新抗原表位。这些患者之间不存在共享的免疫原性表位。然而,我们在一名患者中从CD8(+) TIL中鉴定出一种人类白细胞抗原-C*08:02限制性T细胞受体,该受体靶向在许多人类癌症中发现的KRAS(G12D)热点驱动突变。因此,常见胃肠道癌患者中很大一部分携带免疫原性突变,这些突变有可能被用于开发高度个性化的免疫疗法。